Sulfaphenazole: Precision CYP2C9 Inhibitor for Vascular and Metabolic Research

Executive Summary: Sulfaphenazole is a sulfonamide compound and a highly selective inhibitor of cytochrome P450 enzymes CYP2C6 and CYP2C9, with an IC₅₀ of 0.63 μM for CYP2C9 inhibition (Elmi et al., 2008). It restores endothelium-dependent vasodilation in diabetic mouse models by reducing CYP2C-mediated oxidative stress (DOI). Sulfaphenazole inhibits bacterial dihydropteroate synthase, suppressing folic acid synthesis and displaying antibacterial effects against Mycobacterium tuberculosis, including XDR-TB strains. The compound is water-insoluble but dissolves in DMSO (≥13.15 mg/mL) and ethanol (≥9.92 mg/mL with ultrasonication) and is stable at -20°C (APExBIO). It is widely used in research on drug metabolism, vascular dysfunction, and oxidative stress reduction, with low cytotoxicity (IC₅₀ >64 μg/mL, Vero cells).

Biological Rationale

Cytochrome P450 (CYP) enzymes are critical for drug metabolism and endogenous substrate processing in liver, kidney, and vascular tissues (Elmi et al., 2008). CYP2C9, a prominent isoform, contributes to both xenobiotic metabolism and the generation of reactive oxygen species (ROS) during physiological and pathological states. Upregulation of CYP2C isoenzymes is linked to oxidative stress and endothelial dysfunction, especially in diabetes mellitus and cardiovascular diseases (DOI). Inhibition of CYP2C9 is thus a targeted strategy to dissect metabolic pathways, modulate vascular tone, and study adverse drug reactions and pharmacogenetic variability.

Mechanism of Action of Sulfaphenazole

Sulfaphenazole acts as a competitive inhibitor of CYP2C6 and CYP2C9, binding to the heme active site of these monooxygenases (APExBIO). This inhibition reduces the formation of vasoactive and pro-oxidant metabolites, such as epoxyeicosatrienoic acids and superoxide anions. In bacterial systems, sulfaphenazole competitively inhibits dihydropteroate synthase (DHPS), blocking folic acid synthesis and leading to antibacterial effects. The dual inhibition profile enables research in both mammalian and bacterial metabolism. Sulfaphenazole’s selectivity for CYP2C9 minimizes off-target effects and allows precise attribution of observed phenotypes to CYP2C9 inhibition (see advanced discussion; this article details current translational data, extending the mechanistic depth).

Evidence & Benchmarks

• Sulfaphenazole restores endothelium-dependent vasodilation in diabetic (db/db) mice when administered at 5.13 mg/kg i.p. daily for 8 weeks (Elmi et al., 2008).
• CYP2C9 inhibition by sulfaphenazole (IC₅₀=0.63 μM) reduces oxidative stress markers (8-isoprostane) and increases nitric oxide bioavailability in vivo (DOI).
• In vitro, sulfaphenazole is effective at 0.5–11.5 μM for CYP inhibition assays and 5–30 μg/mL for anti-Mycobacterium tuberculosis activity (APExBIO).
• Sulfaphenazole shows low cytotoxicity (IC₅₀ >64 μg/mL on Vero cells), supporting its use in cellular assays (APExBIO).
• Restoration of vascular function is independent of plasma glucose modulation, indicating a direct effect on endothelial signaling (Elmi et al., 2008).

For protocol optimization, troubleshooting, and advanced use cases, see Sulfaphenazole: Precision CYP2C9 Inhibitor for Translational Research—this article provides new comparative benchmarks and clarifies effective dose ranges under diabetic and injury models.

Applications, Limits & Misconceptions

Applications

• Dissecting drug metabolism and pharmacogenetics involving CYP2C9 (see prior summary; this article updates in vivo efficacy data).
• Studying vascular endothelial function, particularly in diabetic and ischemia-reperfusion injury models (DOI).
• Evaluating antibacterial activity against drug-resistant Mycobacterium tuberculosis, including XDR-TB strains (APExBIO).
• Reducing oxidative stress by specifically inhibiting CYP2C-derived ROS pathways.
• Accelerating wound healing by reducing inflammation and fibrosis and enhancing macrophage bactericidal function.

Common Pitfalls or Misconceptions

• Sulfaphenazole is not a broad-spectrum CYP inhibitor; it is selective for CYP2C6 and CYP2C9 and does not significantly inhibit other major CYP isoforms at standard concentrations.
• It is not suitable for studying CYP3A4, CYP2D6, or non-CYP mediated metabolic pathways.
• Sulfaphenazole’s antibacterial activity is limited to pathways involving dihydropteroate synthase; it is not effective against bacteria lacking this target.
• Due to water insolubility, improper solvent selection (e.g., only aqueous buffers) leads to precipitation and assay interference; DMSO or ethanol are required for stock preparation.
• Chronic high-dose in vivo use beyond validated ranges (e.g., >5.13 mg/kg i.p. daily in mice) lacks safety and efficacy data; off-label escalation is not recommended.

Workflow Integration & Parameters

Sulfaphenazole (SKU C4131) from APExBIO is supplied as a crystalline powder, stable at -20°C for extended periods. For laboratory use, stock solutions are prepared in DMSO (≥13.15 mg/mL) or ethanol (≥9.92 mg/mL with ultrasonication). Working concentrations for CYP inhibition typically range from 0.5–11.5 μM. For anti-tuberculosis assays, 5–30 μg/mL is standard. In cell-based studies, 1–10 μM is effective for modulating CYP2C9 activity. In vivo, 5.13 mg/kg i.p. daily for 8 weeks restores vascular function in diabetic mice (Elmi et al., 2008).

Short-term solution stability is maintained at -20°C, but repeated freeze-thaw cycles are discouraged. For best results, prepare fresh working solutions prior to each experiment. For advanced protocols, see Scenario-Driven Best Practices with Sulfaphenazole; this article provides newly benchmarked storage and dosing data for vascular function assays.

Conclusion & Outlook

Sulfaphenazole is a validated, highly selective CYP2C9 inhibitor with proven utility in both metabolic and vascular research. Its ability to restore endothelial function, reduce oxidative stress, and serve as a model anti-tuberculosis compound underscores its translational value. APExBIO’s Sulfaphenazole (C4131) offers robust reproducibility, low cytotoxicity, and flexible application across in vitro and in vivo platforms. Future research may extend its use in pharmacogenetics and adverse drug reaction modeling, but users should be aware of its selectivity limitations and optimal storage requirements. For detailed product specifications and protocols, visit the APExBIO Sulfaphenazole product page.